BioSpace News Archive

OneOncology, the national platform for independent community oncology practices, and Genentech, a member of the Roche Group, presented data in two abstracts at the 2021 ASCO Quality Care Symposium examining genomic profiling and biomarker testing patterns in community oncology centers, as part of their multi-year strategic research partnership.

ASLAN Pharmaceuticals, a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced positive topline data from its randomized, double-blind, placebo-controlled, 8-week, multiple-ascending-dose Phase 1 study of ASLAN004 for the treatment of moderate-to-severe atopic dermatitis.

Greenwich LifeSciences, Inc. announced that CEO Snehal Patel will present at the Benzinga Healthcare Small-Cap Conference being held September 29-30, 2021.

Ault Global Holdings, Inc. (NYSE American: DPW) a diversified holding company (the “ Company ”), announced that Adtech Pharma, Inc. (“ Adtech ”), has appointed Jodi Brichan, to its Board of Directors. Ms. Brichan was a member of the board of directors of the Company until August 13, 2021.

Cardinal Health plans to release first-quarter financial results for its fiscal year 2022 on November 9 prior to the opening of trading on the New York Stock Exchange.

Cybin Inc. today announced that Doug Drysdale, Chief Executive Officer, will be presenting virtually at two upcoming investor conferences as follows: Cantor Virtual Global Healthcare Conference, Fireside Chat: Date: Thursday, September 30, 2021 Time: 2:00PM ET

TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced the appointment of Roberto Cuca as the Company’s new Chief Operating Officer and Chief Financial Officer.

Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced that the Phase 1 clinical trial of CPI-613® (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma is open for enrollment.

Tvardi Therapeutics (“Tvardi”) today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Ensysce Biosciences, Inc. announced today that it has entered into a securities purchase agreement with institutional investors (“Investors”) in the form of senior secured convertible notes